GGrantIndex
← Leaderboards

Haian Fu

Emory University

$16,783,892
Attributed
$17,816,691
Total exposure
16
Grants
11
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $12M · FY200525
$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$75,156,513 · 20

By mechanism

U54$36,581,016 · 1
P50$12,550,270 · 4
U01$12,012,449 · 3
P01$9,423,251 · 4
R01$3,518,089 · 3
P30$962,785 · 3

Most similar at Emory University

Same institution · by research overlap

Others in their field

Top investigators on “Programs

Research focus

ProgramsMalignant NeoplasmsResearch PersonnelTumorCollaborationsNovel TherapeuticsInnovationMolecularBiologyBaseDrug DiscoveryMemberLeadFundingPathway InteractionsUniversitiesTechnologyResearch Clinical TestingCancer TherapySmall MoleculeCancer PatientResourcesMalignant Neoplasm Of LungTargeted Treatment

Grant awards (79)

Discovery of Antivirals Targeting Mpox Virus$767,057
R01 · FY2025 · AI
Discovery and Developmental Therapeutics Research Program$258,891
P30 · FY2025 · CA · contact PI
Deciphering LKB1-associated immunotherapy resistance in lung adenocarcinoma (LUAD)$2,055,632
P01 · FY2024 · CA · contact PI
Administrative Supplement: Interim Funding for Emory Lung Cancer SPORE$896,274
P50 · FY2024 · CA
Discovery of Antivirals Targeting Mpox Virus$782,142
R01 · FY2024 · AI
Project 2: Reversing STING-mediated immunosuppression in LKB1-mutant lung adenocarcinoma$415,518
P01 · FY2024 · CA · contact PI
Core 1: Administration$148,750
P01 · FY2024 · CA · contact PI
Developmental Research Program$128,039
P50 · FY2024 · CA · contact PI
Discovery and Developmental Therapeutics Research Program$59,398
P30 · FY2024 · CA · contact PI
Open Drug Discovery Center for Alzheimer's Disease$7,132,571
U54 · FY2023 · AG
Deciphering LKB1-associated immunotherapy resistance in lung adenocarcinoma (LUAD)$2,164,833
P01 · FY2023 · CA · contact PI
Emory University Lung Cancer SPORE$1,839,911
P50 · FY2023 · CA
Project 2: Reversing STING-mediated immunosuppression in LKB1-mutant lung adenocarcinoma$390,089
P01 · FY2023 · CA · contact PI
Core 1: Administration$159,419
P01 · FY2023 · CA · contact PI
Developmental Research Program$76,785
P50 · FY2023 · CA · contact PI
Discovery and Developmental Therapeutics Research Program$57,939
P30 · FY2023 · CA · contact PI
Open Drug Discovery Center for Alzheimer's Disease$7,217,536
U54 · FY2022 · AG
Deciphering LKB1-associated immunotherapy resistance in lung adenocarcinoma (LUAD)$2,229,253
P01 · FY2022 · CA · contact PI
Emory University Lung Cancer SPORE$1,839,911
P50 · FY2022 · CA
Project 2: Reversing STING-mediated immunosuppression in LKB1-mutant lung adenocarcinoma$394,856
P01 · FY2022 · CA · contact PI
Core 1: Administration$166,782
P01 · FY2022 · CA · contact PI
Developmental Research Program$97,025
P50 · FY2022 · CA · contact PI
Discovery and Developmental Therapeutics$57,188
P30 · FY2022 · CA · contact PI
Open Drug Discovery Center for Alzheimer's Disease$7,311,958
U54 · FY2021 · AG
Emory University Lung Cancer SPORE$1,825,119
P50 · FY2021 · CA
Systematic discovery of neomorph protein-protein interactions in cancer for oncogenic pathway perturbation$932,391
U01 · FY2021 · CA · contact PI
Developmental Research Program$89,776
P50 · FY2021 · CA · contact PI
Discovery and Developmental Therapeutics$82,644
P30 · FY2021 · CA · contact PI
Open Drug Discovery Center for Alzheimer's Disease$7,420,073
U54 · FY2020 · AG
Emory University Lung Cancer SPORE$1,865,070
P50 · FY2020 · CA
Systematic discovery of neomorph protein-protein interactions in cancer for oncogenic pathway perturbation$932,722
U01 · FY2020 · CA · contact PI
Developmental Research Program$91,922
P50 · FY2020 · CA · contact PI
Discovery and Developmental Therapeutics$82,644
P30 · FY2020 · CA · contact PI
Open Drug Discovery Center for Alzheimer's Disease$7,498,878
U54 · FY2019 · AG
Emory University Lung Cancer SPORE$1,853,913
P50 · FY2019 · CA
Systematic discovery of neomorph protein-protein interactions in cancer for oncogenic pathway perturbation$905,028
U01 · FY2019 · CA · contact PI
Developmental Research Program$89,809
P50 · FY2019 · CA · contact PI
Discovery and Developmental Therapeutics$82,644
P30 · FY2019 · CA · contact PI
Systematic discovery of neomorph protein-protein interactions in cancer for oncogenic pathway perturbation$933,288
U01 · FY2018 · CA · contact PI
Discovery and Developmental Therapeutics$82,644
P30 · FY2018 · CA · contact PI
Discovery and Developmental Therapeutics$13,364
P30 · FY2018 · CA · contact PI
Discovery and Developmental Therapeutics$4,861
P30 · FY2018 · CA · contact PI
Systematic discovery of neomorph protein-protein interactions in cancer for oncogenic pathway perturbation$791,318
U01 · FY2017 · CA · contact PI
Discovery and Developmental Therapeutics$50,360
P30 · FY2017 · CA · contact PI
High Throughput Protein-Protein Interaction Interrogation in Cancer$860,078
U01 · FY2016 · CA · contact PI
DISCOVERY AND DEVELOPMENTAL THERAPEUTICS PROGRAM$28,108
P30 · FY2016 · CA · contact PI
High Throughput Protein-Protein Interaction Interrogation in Cancer$860,078
U01 · FY2015 · CA · contact PI
HIGH THROUGHPUT PROTEIN-PROTEIN INTERACTION INTERROGATION IN CANCER$860,078
U01 · FY2015 · CA · contact PI
DISCOVERY AND DEVELOPMENTAL THERAPEUTICS PROGRAM$28,108
P30 · FY2015 · CA · contact PI
High Throughput Protein-Protein Interaction Interrogation in Cancer$834,276
U01 · FY2014 · CA · contact PI
HIGH THROUGHPUT PROTEIN-PROTEIN INTERACTION INTERROGATION IN CANCER$834,276
U01 · FY2014 · CA · contact PI
DISCOVERY AND DEVELOPMENTAL THERAPEUTICS PROGRAM$25,019
P30 · FY2014 · CA · contact PI
High Throughput Protein-Protein Interaction Interrogation in Cancer$808,473
U01 · FY2013 · CA · contact PI
HIGH THROUGHPUT PROTEIN-PROTEIN INTERACTION INTERROGATION IN CANCER$808,473
U01 · FY2013 · CA · contact PI
DISCOVERY AND DEVELOPMENTAL THERAPEUTICS PROGRAM$22,395
P30 · FY2013 · CA · contact PI
DISCOVERY AND DEVELOPMENTAL THERAPEUTICS PROGRAM$2,339
P30 · FY2013 · CA · contact PI
High Throughput Protein-Protein Interaction Interrogation in Cancer$825,985
U01 · FY2012 · CA · contact PI
HIGH THROUGHPUT PROTEIN-PROTEIN INTERACTION INTERROGATION IN CANCER$825,985
U01 · FY2012 · CA · contact PI
DISCOVERY AND DEVELOPMENTAL THERAPEUTICS PROGRAM$24,239
P30 · FY2012 · CA · contact PI
DEVELOPMENT OF NOVEL CURCUMIN ANALOGS FOR THE TREATMENT OF HEAD AND NECK CANCER$332,688
P50 · FY2011 · CA · contact PI
DEVELOPMENT OF NOVEL CURCUMIN ANALOGS FOR THE TREATMENT OF HEAD AND NECK CANCER$373,491
P50 · FY2010 · CA · contact PI
Targeting 14-3-3-Mediated Survival$312,133
P01 · FY2010 · CA · contact PI
DEVELOPMENT OF NOVEL CURCUMIN ANALOGS FOR THE TREATMENT OF HEAD AND NECK CANCER$402,982
P50 · FY2009 · CA · contact PI
Targeting 14-3-3-Mediated Survival$279,658
P01 · FY2009 · CA · contact PI
DEVELOPMENT OF NOVEL CURCUMIN ANALOGS FOR THE TREATMENT OF HEAD AND NECK CANCER$401,830
P50 · FY2008 · CA · contact PI
Targeting 14-3-3-Mediated Survival$271,666
P01 · FY2008 · CA · contact PI
DEVELOPMENT OF NOVEL CURCUMIN ANALOGS FOR THE TREATMENT OF HEAD AND NECK CANCER$345,725
P50 · FY2007 · CA · contact PI
Targeting 14-3-3-Mediated Survival$269,130
P01 · FY2007 · CA · contact PI
Targeting 14-3-3-Mediated Survival$165,532
P01 · FY2006 · CA · contact PI
Structure and Function of 14 3 3 Proteins$258,084
R01 · FY2005 · GM
AlphaScreen Technology for High Throughput Screenin(RMI)$4,590
R03 · FY2005 · MH
Structure and Function of 14 3 3 Proteins$272,925
R01 · FY2004 · GM
Structure and Function of 14 3 3 Proteins$272,925
R01 · FY2003 · GM
CONTROL OF APOPTOSIS SIGNAL-REGULATING KINASE (ASK) 1$212,800
R01 · FY2003 · GM
Structure and Function of 14 3 3 Proteins$311,656
R01 · FY2002 · GM
CONTROL OF APOPTOSIS SIGNAL-REGULATING KINASE (ASK) 1$212,800
R01 · FY2002 · GM
CONTROL OF APOPTOSIS SIGNAL-REGULATING KINASE (ASK) 1$213,267
R01 · FY2001 · GM
CONTROL OF APOPTOSIS SIGNAL-REGULATING KINASE (ASK) 1$214,433
R01 · FY2000 · GM
STRUCTURE AND FUNCTION OF 14 3 3 PROTEINS$104,063
R29 · FY2000 · GM